Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189395 · ClinicalTrials.gov registry record · Phase 4
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
A Phase 4 study, sponsored by Riverside University Health System Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT02189395: Clinical Trial Phase 4 study, sponsored by Riverside University Health System Medical Center.
NCT02189395 is a Phase 4 study that was terminated before completion, run by Riverside University Health System Medical Center. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02189395, a Phase 4 study, was terminated before completion, sponsored by Riverside University Health System Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of the current study is to determine difference in glycemic control between traditional split mix regimen with Neutral Protamine Hagedorn (NPH) and regular insulin vs basal bolus regimen with glargine and humalog in a population of type 2 diabetes commonly encountered in the investigators county hospital setting which include newly diagnosed type 2 patients and patients on relatively high dose of insulin (dose \>0.4 units/kg body weight. Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose. Secondary outcome is to measure number of hypoglycemic events, number of severe hypoglycemia and length of hospital stay.
Primary Outcome
Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose
Interventions
- DRUG NPH and regular insulin
- DRUG glargine and humalog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 4 |
Why NCT02189395 stopped before completion
NCT02189395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which NPH and regular insulin is the first listed.
NCT02189395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02189395 about?
NCT02189395 is a clinical study titled "Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting". The goal of the current study is to determine difference in glycemic control between traditional split mix regimen with Neutral Protamine Hagedorn (NPH) and regular insulin vs basal bolus regimen with glargine and humalog in a population of type 2 diabetes commonly encountered in the investigators c...
What is the current status of trial NCT02189395?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2013-04. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02189395?
The interventions under investigation include: NPH and regular insulin (DRUG), glargine and humalog (DRUG).
Who is sponsoring clinical trial NCT02189395?
This trial is sponsored by Riverside University Health System Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02189395's enrollment target sits among peer trials
52 1233rd of 2000 higher than 752 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia